J&J's TECVAYLI Plus TALVEY Combo Delivers 89% Risk Reduction in Phase 3 Multiple Myeloma Trial

Johnson & Johnson (JNJ) announced positive topline results from the Phase 3 MonumenTAL-6 trial on July 23, 2026. The combination of TECVAYLI (teclistamab-cqyv) and TALVEY (talquetamab-tgvs) reduced the risk of disease progression or death by 89% (HR 0.11) in relapsed/refractory multiple myeloma. This is the lowest hazard ratio seen across any Phase 3 bispecific therapy study in the disease.

The trial design

MonumenTAL-6 (NCT06208150) was a global, randomized, three-arm Phase 3 study in adult patients with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide. The three arms were:

• TECVAYLI plus TALVEY (Tec-Tal) - the dual bispecific arm
• TALVEY plus pomalidomide (Tal-P)
• Investigator’s choice of EPd or PVd (standard of care)

The primary endpoint was progression-free survival assessed by independent review committee. Key secondary endpoints included overall response rate, complete response or better, MRD-negative complete response, and overall survival.

The results

Both investigational arms met the primary endpoint with statistically significant improvements over standard of care.

The Tec-Tal arm reduced the risk of progression or death by 89% (HR 0.11; 95% CI 0.08-0.16; p<0.0001) and reduced the risk of death by 62% (HR 0.38). The Tal-P arm reduced the risk of progression or death by 73% (HR 0.27; 95% CI 0.2-0.35).

The Independent Data Monitoring Committee recommended unblinding the study at the first interim analysis based on the strength of the data. Full results will be presented at a future medical meeting and shared with global health authorities.

Why dual-antigen targeting matters

TECVAYLI targets BCMA and TALVEY targets GPRC5D, two different proteins found on the surface of myeloma cells. Both are bispecific T-cell engagers, meaning they link T-cells to myeloma cells to trigger immune killing. Using both simultaneously attacks the cancer from two angles, which could overcome resistance mechanisms that let myeloma escape single-target therapies.

This is the first and only Phase 3 study of a dual-antigen bispecific regimen in relapsed/refractory multiple myeloma. The approach is fundamentally different from combining a bispecific with a conventional drug like pomalidomide, though the Tal-P arm also showed a strong 73% risk reduction, giving physicians a flexible option.

The safety profiles of both combination arms were consistent with the known safety profiles of each monotherapy. Both TECVAYLI and TALVEY carry risks of cytokine release syndrome and neurologic toxicity, including ICANS, which is manageable but requires monitoring.

What this means for J&J’s myeloma franchise

This is the fifth positive Phase 3 study for J&J’s multiple myeloma T-cell therapy portfolio. TECVAYLI was already approved in March 2026 in combination with DARZALEX for second-line use. The MonumenTAL-6 data could push bispecific combinations even earlier in the treatment sequence.

J&J’s myeloma portfolio already spans CD38-directed therapies (DARZALEX), BCMA-targeting bispecifics (TECVAYLI), GPRC5D-targeting bispecifics (TALVEY), and cellular therapies. More than 30,700 patients have been treated with TECVAYLI worldwide.

For more on how targeted cancer therapies reach the market, see our Moderna mRNA cancer vaccine analysis.

What to watch next

1. Regulatory submissions: J&J will share results with global health authorities but has not disclosed a filing timeline. The data could support a supplemental filing for the combination.
2. Full data at a future medical meeting: Detailed PFS, OS, response rates, and safety data will give clinicians the complete picture.
3. Competitive implications: Bristol Myers Squibb, Regeneron, and AbbVie all have myeloma bispecifics in development. An HR of 0.11 sets a high competitive bar.

JNJ closed at $259.27 on July 23. As a large-cap diversified healthcare company, JNJ’s stock moves less on single trial readouts than pure-play biotechs, but this strengthens an already dominant myeloma franchise.

Source: Johnson & Johnson press release | ClinicalTrials.gov MonumenTAL-6